公开(公告)号：US11912695B2

公开(公告)日：2024-02-27

申请号：US17574718

申请日：2022-01-13

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D413/14 ,  A61K31/5513 ,  A61P31/14 ,  C07D417/14 ,  A61K45/06

CPC分类号： C07D413/14 ,  A61P31/14 ,  C07D417/14 ,  A61K31/5513 ,  A61K45/06 ,  A61K31/5513 ,  A61K2300/00

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220356189A1

公开(公告)日：2022-11-10

申请号：US16930622

申请日：2020-07-16

申请人： Enanta Pharmaceuticals, Inc.

发明人： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D491/052 ,  C07D471/04

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220323460A1

公开(公告)日：2022-10-13

申请号：US17094029

申请日：2020-11-10

申请人： Enanta Pharmaceuticals, Inc.

发明人： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Kai Lin ,  Michael H.J. Rhodin ,  Nicole V. McAllister ,  Yat Sun Or

IPC分类号： A61K31/5513 ,  C07D491/04 ,  C07D213/12 ,  C07D213/14 ,  A61K31/7056 ,  A61K39/42 ,  A61K39/395 ,  C07D403/12 ,  C07K16/10 ,  C07D217/14 ,  C07D243/24 ,  A61K45/06 ,  C07D217/12 ,  A61K31/4439 ,  C07D498/08 ,  A61P31/14

摘要： The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

公开(公告)号：US10975094B2

公开(公告)日：2021-04-13

申请号：US16379881

申请日：2019-04-10

申请人： Enanta Pharmaceuticals, Inc.

发明人： Jianming Yu ,  Solymar Negretti-Emmanuelli ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D495/14 ,  C07D493/14 ,  C07D413/14 ,  C07D493/10 ,  A61P31/16 ,  C07D519/00

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10570153B2

公开(公告)日：2020-02-25

申请号：US15914016

申请日：2018-03-07

申请人： Enanta Pharmaceuticals, Inc.

发明人： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC分类号： C07D235/24 ,  C07D403/12 ,  C07D513/04 ,  A61K31/56 ,  A61K31/58 ,  A61K31/5513 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190308964A1

公开(公告)日：2019-10-10

申请号：US16449946

申请日：2019-06-24

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： In Jong Kim ,  Jianming Yu ,  Thomas P. Blaisdell ,  Joseph Panarese ,  Brian C. Shook ,  Yat Sun Or

IPC分类号： C07D413/14

摘要： The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to processes and intermediates for the preparation of compounds of formula (I): In particular, the present invention also relates to processes and intermediates for the preparation of compound I-a:

公开(公告)号：US20140187793A1

公开(公告)日：2014-07-03

申请号：US14082406

申请日：2013-11-18

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Yao-Ling Qiu ,  Xiaowen Peng ,  In Jong Kim ,  Hui Cao ,  Datong Tang ,  Yat Sun Or ,  Guoqiang Wang ,  Guoyou Xu

IPC分类号： C07D209/54

CPC分类号： C07D209/54

摘要： The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic):

摘要翻译： 本发明一般涉及一种制备5-氮杂螺[2.4]庚烷-6-羧酸及其衍生物的改进方法，其在合成生物活性分子中是有用的中间体，特别是在合成肝素C病毒NS5A抑制剂 。 特别地，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的方法和中间体：

公开(公告)号：US20140154208A1

公开(公告)日：2014-06-05

申请号：US14092171

申请日：2013-11-27

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Yat Sun Or ,  In Jong Kim ,  Jiang Long ,  Lijuan Jiang ,  Sheng Sean Liu ,  Guoqiang Wang

IPC分类号： C07K7/64 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/13 ,  A61K31/713

CPC分类号： C07K7/645 ,  A61K31/7056 ,  A61K31/713 ,  A61K38/21 ,  A61K45/06 ,  C07K7/64 ,  Y02A50/463 ,  A61K2300/00 ,  A61K38/13

摘要： The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

摘要翻译： 本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US20240360117A1

公开(公告)日：2024-10-31

申请号：US18420855

申请日：2024-01-24

申请人： Enanta Pharmaceuticals, Inc.

发明人： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC分类号： C07D413/14 ,  A61K31/5513 ,  A61K45/06 ,  A61P31/14 ,  C07D417/14

CPC分类号： C07D413/14 ,  A61P31/14 ,  C07D417/14 ,  A61K31/5513 ,  A61K45/06

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230357258A1

公开(公告)日：2023-11-09

申请号：US18131405

申请日：2023-04-06

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Adam Szymaniak ,  Robert Leon ,  Kevin McGrath ,  Xiben Li ,  Tyler J. Mann ,  Jianming Yu ,  In Jong Kim ,  Scott Mitchell ,  Yat Sun Or

IPC分类号： C07D491/048 ,  A61P31/14 ,  A61K45/06 ,  C07D519/00

CPC分类号： C07D491/048 ,  A61P31/14 ,  A61K45/06 ,  C07D519/00 ,  C07B2200/05

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.